Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Columbia University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AIDS Malignancy Consortium
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AIDS Malignancy Consortium
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Emory University
Weill Medical College of Cornell University
University of California, San Francisco
Bispebjerg Hospital
Scripps Translational Science Institute
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Jonsson Comprehensive Cancer Center
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Duke University
AIDS Malignancy Consortium
University of California, San Francisco
City of Hope Medical Center
University of California, San Francisco
AIDS Malignancy Consortium
National Institutes of Health Clinical Center (CC)
AIDS Malignancy Consortium
Latin American Cooperative Oncology Group
Navidea Biopharmaceuticals
Fred Hutchinson Cancer Center
Imperial College London
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Desmond Tutu HIV Foundation
Peking Union Medical College Hospital
Universitas Padjadjaran
University of Aarhus
UNC Lineberger Comprehensive Cancer Center
ANRS, Emerging Infectious Diseases
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Duke University
Indiana University
University Hospital Virgen de las Nieves
Fred Hutchinson Cancer Center
Instituto Nacional de Saúde, Mozambique
AIDS Malignancy Consortium
Indiana University
National Cancer Institute (NCI)